Stockreport

Can-Fite up 36% premarket on advancement of Namodenoson [Seeking Alpha]

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF Can-Fite up 36% premarket on advancement of Namodenoson Thinly traded nano cap Can-Fite BioPharma (NYSEMKT: CANF 36% announcement failed Phase 2 study The company is fin [Read more]